Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

Lenalidomide was combined with pulsed dexamethasone (40 mg/day, days 1–4 and 15–18) after two cycles in five patients, and from the start in three patients (Table 1, patient nos. 9–16).

Lenalidomide, an immunomodulatory agent with antiangiogenic and antineoplastic properties, is a standard treatment for initial and relapsed multiple myeloma.

The combination of lenalidomide and dexamethasone (Len–Dex) is a commonly used initial therapy for newly diagnosed multiple myeloma (MM). Although the initial response rates and toxicity are ...

There was no difference in risk for lenalidomide plus cyclophosphamide, lenalidomide plus dexamethasone, and melphalan alone. "These data suggest that the future role of oral melphalan in ...

Lenalidomide offers an exciting advance in the treatment of the 5q– MDS patient. It has the ability to alter the course of MDS by inducing hematologic and cytogenetic responses, resulting in ...

The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly diagnosed diffuse large B-cell lymphoma, according to study results published in Journal of ...

Lenalidomide is an immunomodulatory agent, prescribed for certain types of myelodysplastic syndrome and multiple myeloma either alone or with other medications. Lenalidomide Interaction with 79 drugs.

Following is a transcript of his remarks: One of the most important questions in myeloma these days is how long you should continue maintenance for. I mean, I'm gonna say five studies and a meta ...

Lenalidomide and daratumumab were each significantly more effective than a placebo when it came to OS, with OR ranges of 1.61 to 1.9 and 1.83 to 2.41, respectively.

If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting REVLIMID treatment.

Phase I data presented at the 2023 American Society of Hematology (ASH) annual meeting showed the benefit of lenalidomide (Revlimid) rechallenge in relapsed/refractory multiple myeloma patients ...